New drug shows promise for slowing kidney disease in Non-Diabetic patients
NCT ID NCT06835322
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested whether finerenone, a drug that blocks a hormone involved in kidney damage, can reduce protein in urine and slow kidney function decline. One hundred adults with non-diabetic glomerulonephritis took either finerenone or a placebo for 9 months, on top of their usual treatments. The goal is to see if finerenone can help protect the kidneys from further damage.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Finerenone (a drug that blocks a hormone to protect the kidneys)
What this could lead to
If it works, finerenone could become an add-on treatment to slow kidney damage and delay dialysis or transplant in people with non-diabetic glomerulonephritis.
What could go wrong
This is a small, phase 2 trial with only 100 participants, so results may not apply to everyone. Finerenone can raise potassium levels, which is a known risk.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLOMERULONEPHRITIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Faculty of Medicine, Aexandria University
Alexandria, 21526, Egypt